Exciting news is on the horizon for women’s health!

Samphire Neuroscience, a cutting-edge medtech startup, just secured an impressive $2.3 million in pre-seed funding to push forward their groundbreaking neurotechnology wearable, Nettle.

This innovative device is set to shake up menstrual health, offering a non-invasive, drug-free solution for managing premenstrual syndrome (PMS) and menstrual pain. It’s a game-changer for the millions of women worldwide who grapple with these challenges every month.

Backing this exciting venture are experienced venture firms like SOSV, FIRSTPICK, Afterwork, Seaside, Ayuh, CVX Ventures, and prominent angel investors Dr. Pamela Walker and Rowena Ironside. Their support underscores the industry’s recognition of the unmet needs in women’s healthcare and the potential of Samphire Neuroscience to fill those gaps.

Leading the charge are Emilė Radytė, a Harvard- and Oxford-educated neuroscientist, and Alex Cook, an Oxford-educated lawyer. Their commitment to redefining women’s healthcare is crystal clear in their flagship product, Nettle—a medical-grade neurostimulation headband designed to tackle both physical and emotional symptoms of menstrual health.

Nettle stands out by targeting not just the prefrontal cortex for mood regulation but also the motor cortex for pain perception, using a technique called transcranial direct current stimulation (tDCS). It’s like hitting two birds with one stone, offering a comprehensive solution for menstrual symptoms.

The science behind Nettle’s efficacy is fascinating.

Research shows a strong link between hormonal fluctuations during the menstrual cycle and changes in brain activity, particularly in mood and pain perception areas. Nettle taps into this knowledge, offering a promising alternative to conventional treatments.

Emilė Radytė, CEO and Co-Founder of Samphire Neuroscience, explains their unique approach, saying,

“We’re looking at things differently—putting the brain at the center of health.”

It’s all about empowering women to prioritize their well-being without compromise.

The pre-seed funding not only shows confidence in Samphire Neuroscience’s vision but also propels the company toward its goals. With plans to speed up clinical research and regulatory approvals, Samphire aims to lead the way in women’s healthcare.

Their ultimate goal?

To arm women with effective tools to manage their menstrual health, leaving behind the era of compromises.

Duncan Turner, General Partner at SOSV, cheers on Samphire’s approach, saying,

“They’re addressing common issues head-on and empowering women to thrive.”

It’s a win-win for everyone involved.

With this funding boost, Samphire Neuroscience can explore Nettle’s potential beyond menstrual health. The possibilities for this innovative approach are endless and could have a significant impact on women’s well-being and healthcare as a whole.

As Samphire Neuroscience sets sail on this transformative journey, the promise of Nettle as a game-changer in women’s healthcare becomes clearer. It’s a beacon of hope for those seeking effective, safe, and non-invasive alternatives for managing menstrual symptoms.

With Nettle leading the charge, Samphire Neuroscience is ready to redefine and elevate the standard of care for women’s health, empowering them in a way that’s both revolutionary and empowering.